• Prostate cancer is the most commonly diagnosed cancer in men.
• Prostate cancer is the leading second cause of cancer death in men.
• An estimated 180,000 men are diagnosed with prostate cancer yearly.
• An estimated 40,000 men will die from prostate cancer yearly.
• There is no known prevention of prostate cancer.
• Having a family member or relative with prostate cancer increases your risk by as much as two-folds.
• Prostate-specific antigen (PSA) is an effective biomarker for the presence of prostate cancer.
• An annual digital rectal exam (DRE) is recommended for all men over 50 or over 40 for men with a family history of prostate cancer or African-American.

In 1995, Dr. Panos G. Koutrouvelis, MD, Director of URPI, developed a new way to treat prostate cancer called, Three-Dimensional (3-D) Computed Tomography (CT)-Guided Pararectal Brachytherapy (3-D CT-Guided Pararectal Brachytherapy). 3-D CT-Guided Pararectal Brachytherapy is patented and FDA-approved.

Dr. Koutrouvelis' innovation brought the ability to treat large volume prostate cancer without pubic arch interference, and improved the precision of seed implant. To date, URPI has treated nearly 1,000 cases of prostate cancer. Some of these patients were not able to undergo other treatment options (i.e. surgery, external-beam radiation therapy, ultrasound-guided brachytherapy, etc...) because of contraindications (i.e. absence of rectum, obesity, presence of penile prosthesis, age over 70 years, calcification of the prostate, etc...).

With 3-D CT-Guided Pararectal Brachytherapy, we treat not only the ideal "low risk" patients, but also intermediate and high risk patients as well. Our results in prostate cancer patients with seminal vesicle invasion, large prostate volume, high and intermediate risk, and patients without rectum have been published in various prestigous scientific journals.